Prothrombotic Biomarkers Are Not Altered by Wood Smoke: A Pilot Controlled Exposure Study.
Dre' Von A Dobson1, Lori A Holle2, Kohei Tatsumi3
1Curriculum in Toxicology and Environmental Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.
FASEB Bioadvances
|July 11, 2025
Summary
Inhaling wood smoke (WS) did not increase blood clotting markers in healthy adults. This study found no significant changes in prothrombotic biomarkers after acute WS exposure.
Area of Science:
- Environmental Health
- Cardiovascular Science
- Hematology
Background:
- Wood smoke (WS) inhalation is linked to cardiovascular events like heart attacks and strokes.
- Vascular occlusion, a key factor in these events, is related to blood clot formation.
- Prothrombotic biomarkers are indicators of the body's clotting activity.
Purpose of the Study:
- To investigate the impact of acute wood smoke (WS) exposure on circulating prothrombotic biomarkers in healthy humans.
- To assess whether WS exposure influences markers of endogenous procoagulant activity.
Main Methods:
- Healthy subjects were exposed to wood smoke (WS) or filtered air for 2 hours.
- Plasma samples were analyzed for tissue factor-positive extracellular vesicles (TF+EVs), thrombin-antithrombin complexes (TAT), D-dimer, and thrombin generation potential.
- Statistical analyses were performed to compare biomarker levels between exposure groups and by sex.
Main Results:
- No significant differences in TF+EVs, TAT, D-dimer, or thrombin generation were observed between individuals exposed to WS and those exposed to filtered air.
- Sex-based differences in TAT and D-dimer were noted, but WS exposure did not alter these markers differently in males or females.
- Acute WS exposure did not elevate plasma prothrombotic biomarkers.
Conclusions:
- Acute inhalation of wood smoke (WS) does not appear to increase circulating prothrombotic biomarkers in healthy individuals.
- These findings suggest that short-term WS exposure may not acutely enhance the risk of thrombotic events through these specific pathways.
- Further research may be needed to explore potential long-term effects or impacts on susceptible populations.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
222
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
349
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
349


